ROLE OF PET/CT IN ASSESSMENT OF POST THERAPEUTIC HEPATOCELLULAR CARCINOM
Sherif Sameh Soliman Hassan;
Abstract
This study aimed to highlight the role of PET/CT in evaluation of post therapeutic hepatocellular carcinoma, hence guiding the clinician to proper management strategy.
The data in our study showed that PET/CT as a metabolic imaging modality could evaluate therapeutic effect and prognostic value in patients with post therapeutic HCC and also can perform full body scanning in a single session and sensitively detect both primary and metastatic tumors.
Our study demonstrated that 18F-FDG PET is a significant prognostic factor for tumor recurrence in post- therapeutic HCC with a cutoff TSUVmax / LSUVmax value of 1.3.
Baseline examination by 18F-FDG PET/CT for the patient before local resection, ablation or embolization of the HCC is very beneficial especially if it shows FDG avidity and increased SUV value before therapy (likely of dedifferentiated type) as the patient will gain great benefit from following up with 18F-FDG PET/CT after the intervention as it help to distinguish viable metabolically active tissue from scar tissues.
The main limitations of PET/CT are motion artifact, CT artifacts, radiation exposure and cost.
So we can conclude that 18F-FDG PET/CT imaging have a prognostic significance in the evaluation of patients with post-therapeutic HCC and provides valuable information that can be used in the treatment response evaluation and clinical decision making process. However, a larger cohort of patients is still needed to validate the results of this study.
References
The data in our study showed that PET/CT as a metabolic imaging modality could evaluate therapeutic effect and prognostic value in patients with post therapeutic HCC and also can perform full body scanning in a single session and sensitively detect both primary and metastatic tumors.
Our study demonstrated that 18F-FDG PET is a significant prognostic factor for tumor recurrence in post- therapeutic HCC with a cutoff TSUVmax / LSUVmax value of 1.3.
Baseline examination by 18F-FDG PET/CT for the patient before local resection, ablation or embolization of the HCC is very beneficial especially if it shows FDG avidity and increased SUV value before therapy (likely of dedifferentiated type) as the patient will gain great benefit from following up with 18F-FDG PET/CT after the intervention as it help to distinguish viable metabolically active tissue from scar tissues.
The main limitations of PET/CT are motion artifact, CT artifacts, radiation exposure and cost.
So we can conclude that 18F-FDG PET/CT imaging have a prognostic significance in the evaluation of patients with post-therapeutic HCC and provides valuable information that can be used in the treatment response evaluation and clinical decision making process. However, a larger cohort of patients is still needed to validate the results of this study.
References
Other data
| Title | ROLE OF PET/CT IN ASSESSMENT OF POST THERAPEUTIC HEPATOCELLULAR CARCINOM | Other Titles | دور التصوير المقطعي بالإنبعاث البوزيتروني المدمج مع الاشعة المقطعية في تقييم ما بعد علاج سرطان الخلايا الكبدية | Authors | Sherif Sameh Soliman Hassan | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.